A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) (NCT07059000)
A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Who can join: Review the eligibility criteria below.
Location: University of Southern California — Los Angeles, California
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- University of Southern California — Los Angeles, California
- NY Cancer and Blood Specialists — Shirley, New York
- East Carolina University — Greenville, North Carolina
- Vseobecna Fakultni Nemocnice v Praze — Prague, Prague
- Fakultni Nemocnice Brno — Brno, South Moravian
- Onkologisches Zentrum Donauwörth Neudegger - Onkomedeor Onkologische Zentren — Donauwörth, Bavaria
- Universitätsklinikum Frankfurt — Frankfurt am Main, Hesse
- Azienda Ospedaliero - Universitaria Careggi — Florence, Florence
- Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara — Novara, Novara
- Azienda Sanitaria Universitaria Giuliano Isontina — Trieste, Trieste
- Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino — Torino, Turin
- AULSS 8 Berica - Ospedale San Bortolo Di Vicenza — Vicenza, Vicenza
- Coltea - Spital Clinic — Bucharest, Bucharest
- Institutul Oncologic Prof. Dr. Ion Chiricuta — Cluj-Napoca, Cluj
- Spitalul Filantropia - Craiova — Craiova, Dolj
- Univerzitetski Klinicki Centar Srbije — Belgrade,
- Klinicko-Bolnicki Centar Zemun — Belgrade,
- Complejo Asistencial Universitario de Burgos - Hospital Universitario de Burgos — Burgos, Burgos
- Instituto De Investigacion Biomedica De A Coruna - Virologia Clinica — A Coruña, La Coruña
- Complejo Hospitalario Ruber Juan Bravo — Madrid, Madrid
- Hospital General Universitario Gregorio Marañón — Madrid, Madrid
- Ankara Üniversitesi Tip Fakültesi - Cebeci Arastirma ve Uygulama Hastanesi — Ankara, Ankara
- Kocaeli Üniversitesi Arastirma ve Uygulama Hastanesi — Ankara, Ankara
- Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi — Yenimahalle, Ankara
- Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi — Edirne, Edirne
📞 Contact the Study Coordinator
Phone: +39 338 6827568
Email: a.lotti@kedrion.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Chronic Primary Immune Thrombocytopenia (ITP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.